Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient?

References

• Al-Herz W, Bousfiha A, Casanova JL, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2014;5:162
   PubMed Web of Science ®Google Scholar
• Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol 2010;125(2 Suppl 2):S182-94
   PubMed Web of Science ®Google Scholar
• Aghamohammadi A, Mohammadinejad P, Abolhassani H, et al. Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry. J Clin Immunol 2014;34(4):478-90
   PubMed Web of Science ®Google Scholar
• Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am 2008;28(2):413-37; x
   PubMed Web of Science ®Google Scholar
• Wood P, Stanworth S, Burton J, et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol 2007;149(3):410-23
   PubMed Web of Science ®Google Scholar
• Rezaei N, Abolhassani H, Aghamohammadi A, Ochs HD. Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev Clin Immunol 2011;7(3):301-16
   PubMed Web of Science ®Google Scholar
• Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American academy of allergy, Asthma and immunology. J Allergy Clin Immunol 2006;117(4 Suppl):S525-53
   PubMed Web of Science ®Google Scholar
• Gathmann B, Binder N, Ehl S, Kindle G; Party ERW. The European internet-based patient and research database for primary immunodeficiencies: update 2011. Clin Exp Immunol 2012;167(3):479-91
   PubMed Web of Science ®Google Scholar
• Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol 2012;32(6):1180-92
   PubMed Web of Science ®Google Scholar
• Hernandez-Trujillo HS, Chapel H, Lo Re VIII, et al. Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol 2012;169(1):57-69
   PubMed Web of Science ®Google Scholar
• Stiehm ER, Orange JS, Ballow M, Lehman H. Therapeutic use of immunoglobulins. Adv Pediatr 2010;57(1):185-218
   PubMedGoogle Scholar
• Yong PL, Boyle J, Ballow M, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clinical immunology 2010;135(2):255-63
   PubMed Web of Science ®Google Scholar
• Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human gamma-globulin. Vox Sang 1962;7:157-74
   PubMed Web of Science ®Google Scholar
• Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am 2008;28(4):737-64; viii
   PubMed Web of Science ®Google Scholar
• Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am 2008;28(4):765-78; viii
   PubMed Web of Science ®Google Scholar
• Silvergleid A, Berger M, Sehrier SL, et al.Overview of intravenous immune globulin (IVIG) therapy. In: Post TW, editor, UpToDate, Waltham, MA. [Last accessed 25 February 2015]
   Google Scholar
• Poelsler G, Berting A, Kindermann J, et al. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity. Vox Sang 2008;94(3):184-92
   PubMed Web of Science ®Google Scholar
• Terpstra FG, Parkkinen J, Tolo H, et al. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product. Vox Sang 2006;90(1):21-32
   PubMed Web of Science ®Google Scholar
• Kreil TR, Wieser A, Berting A, et al. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives. Transfusion 2006;46(7):1143-51
   PubMed Web of Science ®Google Scholar
• Burnouf T, Padilla A. Current strategies to prevent transmission of prions by human plasma derivatives. Transfus Clin Biol 2006;13(5):320-8
   PubMed Web of Science ®Google Scholar
• Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang 2010;98(1):12-28
   PubMed Web of Science ®Google Scholar
• Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm 2005;62(16 Suppl 3):S5-11
   PubMed Web of Science ®Google Scholar
• Papista C, Berthelot L, Monteiro RC. Dysfunctions of the Iga system: a common link between intestinal and renal diseases. Cell Mol Immunol 2011;8(2):126-34
   PubMed Web of Science ®Google Scholar
• Cooper MD, Lanier LL, Conley ME, Puck JM. Immunodeficiency disorders. hematology/ the education program of the american society of hematology. Hematology Am Soc Hematol Educ Program 2003;314-30
   PubMedGoogle Scholar
• Kaveri SV, Maddur MS, Hegde P, et al. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol 2011;164(Suppl 2):2-5
   PubMed Web of Science ®Google Scholar
• Elluru SR, Kaveri SV, Bayry J. The protective role of immunoglobulins in fungal infections and inflammation. Semin Immunopathol 2015;37(2):187-97
   PubMed Web of Science ®Google Scholar
• Siedlar M, Strach M, Bukowska-Strakova K, et al. Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD16++ monocytes in common variable immunodeficiency (CVID) patients. Clin immunol 2011;139(2):122-32
   PubMed Web of Science ®Google Scholar
• Paquin-Proulx D, Santos BA, Carvalho KI, et al. IVIg immune reconstitution treatment alleviates the state of persistent immune activation and suppressed CD4 T cell counts in CVID. PLoS One 2013;8(10):e75199
   PubMed Web of Science ®Google Scholar
• Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006;6(4):592-9
   PubMed Web of Science ®Google Scholar
• Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol 2007;87(3):206-18
   PubMed Web of Science ®Google Scholar
• Siegel J. The product: All intravenous immunoglobulins are not equivalent. Pharmacotherapy 2005;25(11 Pt 2):78S-84S
   PubMed Web of Science ®Google Scholar
• Gurcan HM, Keskin DB, Ahmed AR. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. Autoimmun Rev 2010;9(8):553-9
   PubMed Web of Science ®Google Scholar
• Buehler AM, Flato UP, Ferri CP, Fernandes JG. Is there evidence for recommending specific intravenous immunoglobulin formulations? A systematic review of head-to-head randomized controlled trials. Eur J Pharmacol 2015;747:96-104
   PubMed Web of Science ®Google Scholar
• Saeedian M, Randhawa I. Immunoglobulin replacement therapy: a twenty-year review and current update. Int Arch Allergy Immunol 2014;164(2):151-66
   PubMed Web of Science ®Google Scholar
• Gelfand EW. Differences between IGIV products: Impact on clinical outcome. Int Immunopharmacol 2006;6(4):592-9
   PubMed Web of Science ®Google Scholar
• Pac M. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children]. Pol Merkur Lekarski 2011;30(180):413-16
   PubMedGoogle Scholar
• Garcia-Lloret M, McGhee S, Chatila TA. Immunoglobulin replacement therapy in children. Immunol Allergy Clin North Am 2008;28(4):833-49 , ix.
   PubMed Web of Science ®Google Scholar
• Tcheurekdjian H, Palermo T, Hostoffer R. Quality of life in common variable immunodeficiency requiring intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol 2004;93(2):160-5
   PubMed Web of Science ®Google Scholar
• Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002;109(6):1001-4
   PubMed Web of Science ®Google Scholar
• Pourpak Z, Aghamohammadi A, Sedighipour L, et al. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J Microbiol Immunol Infect 2006;39(2):114-20
   PubMedGoogle Scholar
• Buckley RH. Immunoglobulin G subclass deficiency: fact or fancy? Curr Allergy Asthma Rep 2002;2(5):356-60
   PubMedGoogle Scholar
• Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag 2010;6:1-10
   PubMed Web of Science ®Google Scholar
• Kobrynski LJ. Combined immune deficiencies in children. J Infus Nurs 2006;29(4):206-13
   PubMedGoogle Scholar
• DeWitt CA, Bishop AB, Buescher LS, Stone SP. Hyperimmunoglobulin E syndrome: two cases and a review of the literature. J Am Acad Dermatol 2006;54(5):855-65
   PubMed Web of Science ®Google Scholar
• Mohammadinejad P, Abolhassani H, Aghamohammadi A, et al. Class switch recombination process in ataxia telangiectasia patients with elevated serum levels of IgM. J Immunoassay Immunochem 2015;36(1):16-26
   PubMedGoogle Scholar
• Aghamohammadi A, Imai K, Moazzami K, et al. Ataxia-telangiectasia in a patient presenting with hyper-immunoglobulin M syndrome. J Investig Allergol Clin Immunol 2010;20(5):442-5
   PubMed Web of Science ®Google Scholar
• Renner ED, Hartl D, Rylaarsdam S, et al. Comel-Netherton syndrome defined as primary immunodeficiency. J Allergy Clin Immunol 2009;124(3):536-43
   PubMed Web of Science ®Google Scholar
• Weemaes CM, van Tol MJ, Wang J, et al. Heterogeneous clinical presentation in ICF syndrome: correlation with underlying gene defects. Eur J Hum Genet 2013;21(11):1219-25
   PubMed Web of Science ®Google Scholar
• Wani MA, Haynes LD, Kim J, et al. Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc Natl Acad Sci USA 2006;103(13):5084-9
   PubMed Web of Science ®Google Scholar
• Quinti I, Soresina A, Guerra A, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol 2011;31(3):315-22
   PubMed Web of Science ®Google Scholar
• Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010;125(6):1354-1360 e1354
   PubMed Web of Science ®Google Scholar
• Ballow M. Optimizing immunoglobulin treatment for patients with primary immunodeficiency disease to prevent pneumonia and infection incidence: review of the current data. Ann Allergy Asthma Immunol 2013;111(6 Suppl):S2-5
   PubMed Web of Science ®Google Scholar
• Shehata N, Palda V, Bowen T, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev 2010;24(Suppl 1):S28-50
   PubMed Web of Science ®Google Scholar
• Lederman HM, Winkelstein JA. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine 1985;64(3):145-56
   PubMed Web of Science ®Google Scholar
• Hermaszewski RA, Webster AD. Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications. Q J Med 1993;86(1):31-42
   PubMedGoogle Scholar
• Hansel TT, Haeney MR, Thompson RA. Primary hypogammaglobulinaemia and arthritis. BMJ 1987;295(6591):174-5
   PubMed Web of Science ®Google Scholar
• Aghamohammadi A, Allahverdi A, Abolhassani H, et al. Comparison of pulmonary diseases in common variable immunodeficiency and X-linked agammaglobulinaemia. Respirology 2010;15(2):289-95
   PubMed Web of Science ®Google Scholar
• Mohammadinejad P, Aghamohammadi A, Abolhassani H, et al. Pediatric patients with common variable immunodeficiency: long-term follow-up. J Investig Allergol Clin Immunol 2012;22(3):208-14
   PubMed Web of Science ®Google Scholar
• Aghamohammadi A, Farhoudi A, Moin M, et al. Clinical and immunological features of 65 Iranian patients with common variable immunodeficiency. Clin Diagn Lab Immunol 2005;12(7):825-32
   PubMedGoogle Scholar
• Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clinical immunology 1999;92(1):34-48
   PubMed Web of Science ®Google Scholar
• Aghamohammadi A, Moin M, Farhoudi A, et al. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol 2004;40(2):113-18
   PubMed Web of Science ®Google Scholar
• Aghamohammadi A, Tavassoli M, Abolhassani H, et al. Infectious and non-infectious complications among undiagnosed patients with common variable immunodeficiency. Iran J Pediatr 2009;19(4):367-75
   Web of Science ®Google Scholar
• Abolhassani H, Akbari F, Mirminachi B, et al. Morbidity and mortality of iranian patients with hyper IgM syndrome: a clinical analysis. Iran J Immunol 2014;11(2):123-33
   PubMed Web of Science ®Google Scholar
• Shaghaghi MR, Aghamohammadi A, Abolhassani H, et al. Mortality and morbidity in patients with X-linked agammaglobulinemia. J Clin Immunol 2012;32:297-7
   Web of Science ®Google Scholar
• Aghamohammadi A, Pouladi N, Parvaneh N, et al. Mortality and morbidity in common variable immunodeficiency. J Trop Pediatrics 2007;53(1):32-8
   PubMed Web of Science ®Google Scholar
• Berger M. Adverse effects of IgG therapy. J Allergy Clin Immunol Pract 2013;1(6):558-66
   PubMed Web of Science ®Google Scholar
• Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol 2011;11(6):532-8
   PubMed Web of Science ®Google Scholar
• Malbran A, Larrauri B, Juri MC, Fernandez Romero DS. [Adverse events in 1395 infusions with different intravenous gammaglobulin products]. Medicina (B Aires) 2013;73(5):433-7
   PubMed Web of Science ®Google Scholar
• Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006;6(4):535-42
   PubMed Web of Science ®Google Scholar
• Rault R, Piraino B, Johnston JR, Oral A. Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol 1991;36(2):83-6
   PubMed Web of Science ®Google Scholar
• Gupta N, Ahmed I, Nissel-Horowitz S, et al. Intravenous gammaglobulin-associated acute renal failure. Am J Hematol 2001;66(2):151-2
   PubMed Web of Science ®Google Scholar
• Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 2008;51(3):491-503
   PubMed Web of Science ®Google Scholar
• Bern M. Clinically significant pseudohyponatremia. Am J Hematol 2006;81(7):558-9
   PubMed Web of Science ®Google Scholar
• Steinberger BA, Ford SM, Coleman TA. Intravenous immunoglobulin therapy results in post-infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia. Am J Hematol 2003;73(2):97-100
   PubMed Web of Science ®Google Scholar
• Miller JL, Petteway SRJr, Lee DC. Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma-derived therapeutic proteins. J Allergy Clin Immunol 2001;108(4 Suppl):S91-4
   PubMed Web of Science ®Google Scholar
• Caress JB, Cartwright MS, Donofrio PD, Peacock JEJr. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 2003;60(11):1822-4
   PubMed Web of Science ®Google Scholar
• Mizrahi M, Adar T, Orenbuch-Harroch E, Elitzur Y. Non-ST elevation myocardial infraction after high dose intravenous immunoglobulin infusion. Case Rep Med 2009;2009:861370
   Google Scholar
• Katz KA, Hivnor CM, Geist DE, et al. Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. Arch Dermatol 2003;139(8):991-3
   PubMed Web of Science ®Google Scholar
• Byrne NP, Henry JC, Herrmann DN, et al. Neuropathologic findings in a Guillain-Barre patient with strokes after IVIg therapy. Neurology 2002;59(3):458-61
   PubMed Web of Science ®Google Scholar
• Mizrahi M. The hypercoagulability of intravenous immunoglobulin. Clin Adv Hematol Oncol 2011;9(1):49-50
   PubMedGoogle Scholar
• Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000;65(1):30-4
   PubMed Web of Science ®Google Scholar
• Funk MB, Gross N, Gross S, et al. Thromboembolic events associated with immunoglobulin treatment. Vox Sang 2013;105(1):54-64
   PubMed Web of Science ®Google Scholar
• Notarangelo LD, Plebani A, Mazzolari E, et al. Genetic causes of bronchiectasis: Primary immune deficiencies and the lung. Respiration 2007;74(3):264-75
   PubMed Web of Science ®Google Scholar
• de Gracia J, Vendrell M, Alvarez A, et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 2004;4(6):745-53
   PubMed Web of Science ®Google Scholar
• Chen Y, Stirling RG, Paul E, et al. Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies. J Allergy Clin Immun 2011;127(6):1414-17
   PubMed Web of Science ®Google Scholar
• Warrier I, Bussel JB, Valdez L, et al. Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group. J Pediatr Hematol Oncol 1997;19(3):197-201
   PubMed Web of Science ®Google Scholar
• Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008;48(8):1598-601
   PubMed Web of Science ®Google Scholar
• Rachid R, Bonilla FA. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature. J Allergy Clin Immunol 2012;129(3):628-34
   PubMed Web of Science ®Google Scholar
• IUIS/WHO notice. Appropriate uses of human immunoglobulin in clinical practice. Clin Exp Immunol 1983;52(2):417-22
   PubMed Web of Science ®Google Scholar
• WHO. WHO recommendations for the production, control, and regulation of human plasma for fractionation. World Health Organization; Geneva, Switzerland: 2005
   Google Scholar
• Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion 2003;43(10):1460-80
   PubMed Web of Science ®Google Scholar
• Guillevin L. [Indications for immunoglobulins. Recommendations of CEDIT of AP-HP in 2006]. Rev Med Interne 2007;28(Spec No 1):1-3
   PubMed Web of Science ®Google Scholar
• Frauger E, Grassi J, Pradel V, et al. Use of intravenous immunoglobulins in clinical practice: data from three French university hospitals. Fundam Clin Pharmacol 2011;25(6):753-61
   PubMed Web of Science ®Google Scholar
• Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007;6(4):257-9
   PubMed Web of Science ®Google Scholar
• Katz U, Kishner I, Magalashvili D, et al. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience. Autoimmunity 2006;39(6):513-17
   PubMed Web of Science ®Google Scholar
• Gelfand EW. Critical decisions in selecting an intravenous immunoglobulin product. J Infus Nurs 2005;28(6):366-74
   PubMedGoogle Scholar